AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

One of the new mechanics added in Marvel Rivals Season 1 was Recursive Destruction, and fans have been quite curious to know what it is all about. Marvel Rivals offers a variety of different maps that ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Invoking DurableTaskClient.PurgeInstanceAsync with PurgeInstanceOptions.Recursive = true does not result in sub-orchestrations being purged. The documentation for this method states that ...

The biotech uses one of the world’s largest datasets and AI supercomputers to find new drugs, but continued losses and lack of commercial products keep risk levels high. Recursion Pharmaceuticals is a ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...